- PhD in Biochemistry, University of Cambridge
- Executive MBA, IE Business School
Fermín has vast experience in evaluating drug discovery, medical device and IVD projects as he was previously director of evaluation at Najeti Capital and Uninvest SCR where he evaluated more than 150 projects.
Between 2004 and 2008, he held the position of Licensing Manager at Esteve, actively participating in the project teams for products in development. There, he also formed part of the executive R&D committee that discussed all the scientific data and development strategies.
In 2008, he joined Metasbio as a partner and senior consultant, where he drafted business plans for several pharmaceutical, chemical and IVD companies and took an active part in implementing them.
He subsequently became CEO of Proretina Therapeutics, a company that developed therapies for retinal illnesses, head of Business Development at Pangaea Oncology and head of licensing of the p21-activated kinase (PAK) inhibitor drugs programme at Cancer Research Technologies (CRT) in the UK. For two years, he participated in the joint project team of CRT and Pangaea, which discusses how to optimise products and analyse them through HTS.